Deals Of The Week: Shionogi-Sciele/Victory; GSK/OBT; Novartis/Elixir
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
GSK Takes An Option On Concert’s Preclinical Compounds
In the latest in a long string of alliances sporting options, the Big Pharma lends its imprimatur to Concert’s platform for creating deuterated versions of existing molecules.
GSK Takes An Option On Concert’s Preclinical Compounds
In the latest in a long string of alliances sporting options, the Big Pharma lends its imprimatur to Concert’s platform for creating deuterated versions of existing molecules.
Onyx Accuses Bayer of a Double-Cross Over a Compound Related to Nexavar
Bayer pursued a “surreptitious” plan to supplant the cancer drug at the heart of a 15-year-old collaboration, according to a harshly-worded lawsuit.